Heading into an important year, there is a case on paper for Nu Skin Enterprises ( NUS ) stock. Shares are cheap, trading in the range of 3x adjusted EBITDA for 2026. Guidance for this year does seem to have disappointed, sending shares lower, but marginsI've been contributing to Seeking Alpha and other investment websites since 2011, with a general (though far from rigid) focus on value over growth. I got my Series 7 and 63 back in 1999, and watched the dot-com bubble peak and then burst in real time at a ...

Core Viewpoint - Nu Skin (NUS) is identified as a potential turnaround stock, but its recovery may not be fully realized by 2026 due to a shrinking market for its skincare products, typical of multi-level marketing (MLM) companies [1]. Company Summary - Nu Skin operates in the skincare product sector and is categorized as a multi-level marketing company, which has been experiencing a decline in market size [1]. - The company's current trading position reflects the challenges faced within the MLM industry, indicating a need for strategic changes to achieve a successful turnaround [1].

Aristotle Capital Boston, LLC, an investment advisor, released its fourth-quarter investor letter for “Small Cap Equity Fund”. A copy of the letter can be downloaded here. U.S. small-cap equities reported modest gains in the fourth quarter of 2025. The quarter started as a continuation of the post-Liberation Day risk-on market environment, while it ended on a strong note, driven by a positive macroeconomic backdrop. Attractive valuations, earnings recovery, broadening of the market, and a shift from mega-ca ...

Core Insights - Nu Skin Enterprises, Inc. (NUS) reported fourth-quarter 2025 results that fell short of Zacks Consensus Estimates, with both earnings and net sales declining year over year [1][10]. Financial Performance - Adjusted earnings for the fourth quarter were 29 cents per share, down from 38 cents per share in the same quarter last year, missing the consensus estimate of 30 cents [1][10]. - Quarterly revenues totaled $370.3 million, a decline of 16.9% year over year, with a negative impact of 0.2% from foreign currency fluctuations. On a constant-currency basis, revenues fell 16.7% [2][10]. - Adjusted gross profit was $262 million, down 17.6% from $317.9 million in the prior year, with an adjusted gross margin of 70.7%, a decrease of 70 basis points from the previous year [3][5]. - Selling expenses decreased by 20.6% to $131.3 million, representing 35.5% of revenues, down 160 basis points from the prior year [4][5]. - General and administrative expenses were $107.4 million, down 11.2% year over year, but as a percentage of revenues, they increased to 29% [5]. Customer and Sales Metrics - Sales leaders decreased by 19% year over year to 30,045, while the customer base dropped by 10% to 748,796. Paid affiliates also fell by 11% to 129,311 [2][10]. - Region-wise revenue declines were noted across various markets, with the Americas down 9.8% and Southeast Asia/Pacific down 22.7% [6]. Future Guidance - For 2026, Nu Skin anticipates revenues between $1.35 billion and $1.50 billion, indicating a potential decline of 9% to 1% from the previous year, with EPS expected to be between 80 cents and $1.20 [11][10]. - The first quarter of 2026 is projected to see revenues between $320 million and $340 million, reflecting a decline of 7-12% [12]. Financial Health - At the end of the quarter, the company had cash and cash equivalents of $238.6 million, long-term debt of $204.2 million, and total stockholders' equity of $805.2 million [7]. - The company declared a cash dividend of 6 cents per share, payable on March 11, 2026 [8].

Core Insights - NU Skin Enterprises Inc. reported revenue of $370.3 million, adjusted net income of $14.5 million, and adjusted EPS of $0.29, which were below estimates of $380.2 million, $15.1 million, and $0.30 respectively, indicating weaker-than-expected top-line results [1] - The results were at the low end of revenue guidance and the high end of EPS guidance, with a gross margin of 77.6% for the Nu Skin business [1] - Management emphasized strategic penetration into India and other emerging markets, along with margin expansion and a one-time tax benefit, as key contributors to the EPS results for FY25 [1] Financial Performance - Revenue from Rhyz was $48.52 million, comprising $42.45 million from Manufacturing and $6.07 million from Rhyz Other [1] - Selling expenses for the core business decreased to 40.8%, reflecting disciplined spending [1] Strategic Initiatives - Management remains focused on executing strategic initiatives despite the weaker top-line results [1] - The rollout of Prism iO is advancing with a pre-launch in India underway, and a full opening expected in the second half of FY26 [7] - FY26 EPS guidance is set at a midpoint of $1.00 [7]

Core Insights - The consumer staples sector has identified oversold stocks, presenting potential investment opportunities in undervalued companies [1] - The Relative Strength Index (RSI) is a key momentum indicator used to assess stock performance, with an RSI below 30 indicating that a stock is considered oversold [1] Oversold Stocks List - Notable companies with an RSI near or below 30 include NU Skin Enterprises Inc (NYSE:NUS), Coty Inc (NYSE:COTY), and Honest Company Inc (NASDAQ:HNST) [2][3]

Napierski positioned Prysm iO as a central part of the company’s move into the “wellness revolution,” describing it as a non-invasive carotenoid measurement device designed to provide insights across four domains: diet, fitness, lifestyle, and nutritional supplementation. He said Nu Skin is building on its portfolio of connected devices and its BioPhotonic Scanner technology.Napierski described “switching costs” tied to changes in business practices during 2025 and into early 2026, but said the company beli ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-12421 NU SKIN ENTERPRISES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

Core Insights - Nu Skin Enterprises reported quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.30 per share, and down from $0.38 per share a year ago [1] - The company posted revenues of $370.32 million for the quarter, missing the Zacks Consensus Estimate by 3.24%, and down from $445.55 million year-over-year [3] Earnings Performance - The earnings surprise for the quarter was -3.33%, with the company having surpassed consensus EPS estimates only once in the last four quarters [2] - A quarter ago, the company had an earnings surprise of +13.33% when it reported earnings of $0.34 per share against an expectation of $0.30 [2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.27 on revenues of $356.8 million, and for the current fiscal year, it is $1.42 on revenues of $1.53 billion [8] - The estimate revisions trend for Nu Skin was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [7] Industry Context - The Cosmetics industry, to which Nu Skin belongs, is currently in the bottom 20% of the Zacks Industry Rank, which may negatively impact stock performance [9] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can significantly affect stock performance [6][9]

Financial Data and Key Metrics Changes - For 2025, the company reported adjusted earnings per share of $1.27, up from $0.84 in the previous year, representing a 51% growth [17] - Revenue for the full year was $1.49 billion, within the original guidance, with a foreign currency headwind of approximately $13.4 million [20] - The fourth quarter revenue was $370 million, with earnings per share of $0.29, aligning with expectations [18] Business Line Data and Key Metrics Changes - The gross margin for the core Nu Skin business finished at 77.4%, an 80 basis point improvement over the prior year [20] - Selling expense for the core Nu Skin business was 40.3% for the year, with expectations to remain around 40% moving forward [21] - The operating margin for the full year improved to 6.7%, up 140 basis points from the previous year [22] Market Data and Key Metrics Changes - The company initiated pre-market operations in India in November 2025, with a formal market opening anticipated in late 2026 [5] - Latin America continues to show strong performance, contributing positively to the company's growth [24] - The company is focusing on establishing operational infrastructure in India, including local manufacturing and logistics partnerships [14] Company Strategy and Development Direction - The company aims to become the world's leading intelligent beauty, wellness, and lifestyle leadership opportunity platform, focusing on three strategic priorities: launching the Prysm iO platform, expanding into emerging markets like India, and improving operational performance [6][12] - Prysm iO is positioned as a customer acquisition tool with subscription-based revenue, expected to enhance customer lifetime value significantly [11] - The company is targeting to place over 100,000 Prysm iO devices by the end of 2026, with aspirations to reach 10 million households by 2030 [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to growth by the end of 2026, despite inherent switching costs associated with transitioning the business [5] - The company is cautious about revenue projections for India, emphasizing the importance of establishing local infrastructure before the formal launch [36] - Management highlighted the importance of maintaining disciplined execution and financial performance while pursuing growth opportunities [26] Other Important Information - The company ended the quarter with approximately $240 million in cash and reduced outstanding debt to $224 million, resulting in an expanded net cash position [23] - The company returned approximately $11.8 million in dividends and $20 million in share repurchases during the year [23] Q&A Session Summary Question: Insights on Prysm's revenue contribution - Management indicated that the placement of Prysm devices will lead to subscriptions, with an estimated market value of around $300 per device, potentially generating $30 million from device sales alone [33] Question: Thoughts on India market potential - Management sees long-term potential in India but is cautious about immediate revenue forecasts, focusing on establishing local manufacturing and logistics [36][37] Question: Guidance and key leverage points - Management discussed the importance of gross margin expansion and maintaining selling expenses around 40% while managing G&A costs in line with revenue [39][41] Question: Other portfolio performance insights - Management highlighted the successful rollout of the Tru Face skincare line and ongoing improvements in various markets, including China and Latin America [43][45]